Nolvamed 20

Description

Product Description: Nolvamed 20

Nolvamed 20 is a highly regarded product from the esteemed brand Deus, known for its effective antiestrogenic properties. Its primary active ingredient, Tamoxifen Citrate, is well-documented for its ability to inhibit estrogen activity in the body. Upon ingestion, Nolvamed 20 is absorbed through the intestine, where it binds to plasma albumin, facilitating its distribution throughout various tissues. This competitive binding process with estrogen receptors inhibits estrogen from exerting its effects in certain areas of the body, thus providing a therapeutic advantage in both hormonal balance and overall health.

Key Benefits:
– Anti-Estrogenic Action: Nolvamed 20 competes with estrogens for receptor sites, effectively blocking their action.
– Cholesterol Management: It has been shown to lower total cholesterol levels, particularly reducing LDL cholesterol, while preserving bone mineral density—a crucial factor in preventing osteoporosis.
– Cardiovascular Protection: By managing estrogen’s effects and reducing cholesterol, it provides cardiovascular protection.
– Testosterone Stimulation: Nolvamed 20 also promotes the natural production of Testosterone. It does so by inhibiting the negative feedback mechanism exerted by estrogen on the hypothalamus and pituitary gland. This results in an increased secretion of Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH), essential hormones for stimulating Testosterone production.

Dosage Guidelines:
– For Cycle Support: Take 1 capsule containing 20 mg of the active ingredient once daily during cycles to help mitigate the side effects associated with estrogen conversion.
– Post-Cycle Therapy (PCT): Following a cycle, it is recommended to take 1 to 2 tablets daily for 4-6 weeks to support recovery of natural hormone levels.
– Half-Life: The half-life of Nolvamed 20 is approximately 5-7 days, which allows for a consistent therapeutic effect.

With its comprehensive benefits and well-structured dosage regimen, Nolvamed 20 stands as a valuable addition to any regimen aimed at managing hormonal health and enhancing performance.

1. “Tamoxifen (Nolvadex), a hormone therapy drug” da Cancer Research UK, 2020. (https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/tamoxifen)

2. “Tamoxifen in men: a review of adverse events” di Wibowo E, Pollock PA, Hollis N, Wassersug RJ. in Andrology. 2016 Oct;4(5):776-88. (https://pubmed.ncbi.nlm.nih.gov/27544718/)

3. “Selective estrogen receptor modulators and risk for coronary heart disease” di Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. in Circulation. 2006 May 2;113(17):2033-40. (https://pubmed.ncbi.nlm.nih.gov/16651470/)

4. “Prevention of bone loss by tamoxifen in postmenopausal women with breast cancer: A German, multicenter, prospective study” di Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kalder M, Kuck J, Hasenburg A. in Journal of Clinical Oncology. 2009;27(15S):533. (https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15s.533)

5. “Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3” di Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R, in Cancer Research. 2004 Feb 15;64(4):1390-8. (https://pubmed.ncbi.nlm.nih.gov/14973115/)

6. “Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma” di Silvestre G, Portuese A, Angelucci M, et al. in Gynecol Oncol. 2000 Mar;76(3):362-6. (https://pubmed